EXHIBIT 99.1
FOR IMMEDIATE RELEASE:
 
ABMC REPORTS FOURTH QUARTER AND YEAR END 2019 RESULTS
 
Kinderhook, N.Y., June 26, 2019 American Bio Medica Corporation (OTCPK: ABMC) today announced financial results for the fourth quarter and year ended December 31, 2019.
Chief Executive Officer, Melissa A. Waterhouse stated, “While sales did not increase in Q4 2019 (as they did in Q3 2019), they were relatively flat. In 2019, sales in our core markets declined, some of which was due to timing of shipments to customers at the end of the year. These declines were partially offset by increased contract manufacturing sales (due to two new customers in 2019) along with increased international sales. Operational expenses declined due to continued efforts to control costs wherever possible.”
 
Waterhouse continued, “Our drug testing business has been negatively impacted by the Covid-19 pandemic in the first half of 2020. The core markets for our drug tests are employment, clinical and government; and each of these sectors has been negatively impacted by the pandemic in various ways. On March 23, 2020, we announced we are distributing a rapid antibody test for Covid-19 and on May 29, 2020 this COVID-19 test was authorized by the United States Food and Drug Administration (FDA) under an Emergency Use Authorization (EUA) for use by authorized laboratories. Starting in late March 2020, we conducted pre-sales of the product and began shipping orders to customers in May 2020. Sales of the Rapid Covid-19 test have offset the negative impact to our drug testing business. As of the date of this release, we have recorded revenues of just over $1,000,000 which resulted in approximately $430,000 in profit to ABMC after expenses and commissions.”
 
Financial Highlights
 
Net sales in the fourth quarter of 2019 were $880,000, compared to $884,000 in the fourth quarter of 2018, or relatively flat. Net sales in 2019 were $3,655,000, compared to net sales of $3,872,000 in 2018, a decrease of 5.6%.
 
Operating loss was $183,000 in the fourth quarter of 2019, compared to an operating loss of $348,000 in the fourth quarter of 2018. Operating loss in 2019 was $593,000 compared to an operating loss of $762,000 in 2018.
 
Net loss was $248,000 in the fourth quarter of 2019, compared to a net loss of $412,000 in the fourth quarter of 2018. Net loss was $681,000 in 2019, compared to a net loss of $1,028,000 in 2018.
 
For more information on ABMC or its drug testing products, please visit www.abmc.com.
 
About American Bio Medica Corporation
 
American Bio Medica Corporation manufactures and markets accurate, cost-effective immunoassay test kits, primarily point of collection tests for drugs of abuse and distributes a rapid test to detect Covid-19 antibodies. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets.
 
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, future sales and profit levels of the rapid antibody test for Covid-19 that we are distributing, product development, compliance with regulatory requirements, including but not limited to our ability to obtain marketing clearance on our product for our intended markets, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to “penny stock” rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled “Risk Factors” in the Company's annual report on Form 10-K for the year ended December 31, 2018, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.
 
(financial tables follow)
 
 
1
 
  
American Bio Medica Corporation
Statements of Operation
 
 
 
Three Months Ended
 
 
Year Ended
 
 
 
December 31,
 
 
December 31,
 
 
 
2019
 
 
2018
 
 
2019
 
 
2018
 
 
 
(unaudited)
 
 
(unaudited)
 
 
(unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net sales
 $880,000 
 $884,000 
 $3,655,000 
 $3,872,000 
Cost of goods sold
  666,000 
  768,000 
  2,471,000 
  2,584,000 
       Gross profit
  214,000 
  116,000 
  1,184,000 
  1,288,000 
Operating expenses:
    
    
    
    
  Research and development
  20,000 
  29,000 
  82,000 
  93,000 
  Selling and marketing
  109,000 
  111,000 
  459,000 
  545,000 
  General and administrative
  268,000 
  324,000 
  1,236,000 
  1,412,000 
       Total operating expenses
  397,000 
  464,000 
  1,777,000 
  2,050,000 
 
    
    
    
    
Operating loss
  (183,000)
  (348,000)
  (593,000)
  (762,000)
 
    
    
    
    
Other income/(expense) - net
  (65,000)
  (64,000)
  (93,000)
  (264,000)
 
    
    
    
    
Net loss before tax
  (248,000)
  (412,000)
  (686,000)
  (1,026,000)
 
    
    
    
    
Income tax expense
  8,000 
  (1,000)
  5,000 
  (2,000)
 
    
    
    
    
Net loss
  (240,000)
  (413,000)
  (681,000)
  (1,028,000)
 
    
    
    
    
Basic & diluted loss per common share
 $(0.01)
 $(0.01)
 $(0.02)
 $(0.03)
 
    
    
    
    
Basic weighted average shares outstanding
  32,667,757 
  29,211,454 
  32,526,669 
  30,115,063 
Diluted weighted average shares outstanding
  32,667,757 
  29,211,454 
  32,526,669 
  30,115,063 
 
(Balance Sheets follow)
 
 
2
 
  
American Bio Medica Corporation
Balance Sheets
 
 
 
December 31,
2019
(unaudited)
 
 
December 31,
2018
 
ASSETS
 
 
 
 
 
 
Current Assets
 
 
 
 
 
 
Cash and cash equivalents
 $4,000 
 $113,000 
Accounts receivable, net of allowance for doubtful accounts of $34,000 at December 31, 2019 and $36,000 at December 31, 2018
  370,000 
  452,000 
Inventory, net of allowance of $291,000 at December 31, 2019 and $268,000 at December 31, 2018
  810,000 
  1,019,000 
Prepaid expenses and other current assets
  6,000 
  29,000 
Right of Use Asset – Operating Leases
  37,000 
  0 
Total current assets
  1,227,000 
  1,613,000 
Property, plant and equipment, net
  644,000 
  718,000 
Patents, net
  116,000 
  123,000 
Right of Use Asset – Operating Leases
  73,000 
  0 
Other assets
  21,000 
  21,000 
Total assets
 $2,078,000 
 $2,475,000 
 
    
    
LIABILITIES AND STOCKHOLDERS' EQUITY
    
    
Current liabilities
    
    
Accounts payable
 $652,000 
 $359,000 
Accrued expenses and other current liabilities
  543,000 
  449,000 
Right of Use Liability – Operating Leases
  34,000 
  0 
Wages payable
  104,000 
  278,000 
Line of credit
  337,000 
  502,000 
Current portion of long-term debt, net of deferred finance costs
  17,000 
  237,000 
Total current liabilities
  1,687,000 
  1,825,000 
     Long term debt, net of current portion & deferred finance costs
  1,108,000 
  796,000 
     Right of Use Liability – Operating Leases
  73,000 
  0 
Total liabilities
  2,868,000 
  2,621,000 
 
    
    
Stockholders' Equity:
    
    
Common stock
  327,000 
  323,000 
Additional paid-in capital
  21,437,000 
  21,404,000 
Accumulated deficit
  (22,554,000)
  (21,873,000)
Total stockholders’ equity
  (790,000)
  (146,000)
Total liabilities and stockholders' equity
 $2,078,000 
 $2,475,000 
 
#####
 
 
3

View differences made from one to another to evaluate American Bio Medica Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by American Bio Medica Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account